Loading...

Purified anti-human CD28 Antibody

Pricing & Availability
Clone
CD28.2 (See other available formats)
Regulatory Status
RUO
Workshop
V-CD28.05
Other Names
T44, Tp44
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
28.2
Human peripheral blood lymphocytes stained with CD28.2 PE
  • 28.2
    Human peripheral blood lymphocytes stained with CD28.2 PE
Compare all formats
Cat # Size Price Quantity Check Availability Save
302901 25 µg 24 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302902 100 µg 50 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD28 is a 44 kD disulfide-linked homodimeric type I glycoprotein. It is a member of the immunoglobulin superfamily and is also known as T44 or Tp44. CD28 is expressed on most T lineage cells, NK cell subsets, and plasma cells. CD28 binds both CD80 and CD86 using a highly conserved motif MYPPY in the CDR3-like loop. CD28 is considered a major co-stimulatory molecule, inducing T lymphocyte activation and IL-2 synthesis, and preventing cell death. In vitro studies indicate that ligation of CD28 on T cells by CD80 and CD86 on antigen presenting cells provides a costimulatory signal required for T cell activation and proliferation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Baboon, Capuchin Monkey, Chimpanzee, Pigtailed Macaque, Sooty Mangabey, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F, Costim, FA - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per 106 cells in 100 µl volume or 100 µl whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for highly sensitive assays.

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Nunes J, et al. 1993. Biochem. J. 293:835.
  3. Calea-Lauri J, et al. 1999. J. Immunol. 163:62.
  4. Tazi A, et al. 1999. J. Immunol. 163:3511. (IHC)
  5. Marti F, et al. 2001. J. Immunol. 166:197. (Costim)
  6. Jeong SH, et al. 2004. J. Virol. 78:6995. (Costim)
  7. Rivollier A, et al. 2004. Blood 104:4029. (Costim)
  8. Scharschmidt E, et al. 2004. Mol. Cell Biol. 24:3860. (Costim)
  9. Sheng W, et al. 2007.Elsevier 580:6819. PubMed
  10. Mitsuhashi M. 2007. Clin Chem.53:148. PubMed
  11. Ye Z, et al. 2008. Infect. Immun. 76:2541. PubMed
  12. Magatti M, et al. 2008. Stem Cells 26:182. (FA) PubMed
  13. Yoshino N, et al. 2008. Exp. Anim. (Tokyo) 49:97. (FC)
  14. Berg M, et al. 2008. J Leukoc Biol. 83:853. (IP) PubMed
  15. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  16. Leonard JA, et al. 2011. J. Virol. 85:6867. PubMed
  17. Nomura T, et al. 2012. J. Virol. 86:6481. PubMed
Product Citations
  1. Liu L, et al. 2016. Nat Biotechnol. 10.1038/nbt.3461. PubMed
  2. Panigrahi S, et al. 2020. PLoS Pathog. e1008885:16. PubMed
  3. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
  4. Mitsuhashi M 2007. Clin Chem. 53:148. PubMed
  5. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  6. Kim SJ, et al. 2020. J Biol Chem. 296:100108. PubMed
  7. Alpert A, et al. 2022. Cell Syst. 13:71. PubMed
  8. Saito T, et al. 2022. ACS Chem Biol. 17:217. PubMed
  9. Toothaker JM, et al. 2022. Development. 149: . PubMed
  10. Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed
  11. Kim HS, et al. 2023. Bioact Mater. 21:241. PubMed
  12. Onnis A, et al. 2023. J Exp Med. 220: . PubMed
  13. Chai H, et al. 2023. Nat Commun. 14:213. PubMed
  14. Poon MML, et al. 2023. Nat Immunol. 24:309. PubMed
  15. Mohamed H, et al. 2023. Biomedicines. 11: . PubMed
  16. Schnizer C 2022. Frontiers in Immunology. 13:1095129. PubMed
  17. Davé E, et al. 2023. MAbs. 15:2160229. PubMed
  18. Pymm P, et al. 2022. Cell Rep. 38:110449. PubMed
  19. Giles JR, et al. 2022. Immunity. 55:557. PubMed
  20. Duan LJ, et al. 2022. Cell Rep. 40:111284. PubMed
  21. Chen L, et al. 2023. Immunology. 169:204. PubMed
  22. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  23. Meadows AM, et al. 2023. iScience. 26:106578. PubMed
  24. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  25. Eberhardt F, et al. 2023. Int J Mol Med. 52:. PubMed
  26. Friebel E, et al. 2020. Cell. 181(7):1626-1642.e20. PubMed
  27. Zhang Y, et al. 2019. Cell Res. 29:609. PubMed
  28. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
  29. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
  30. Taft J, et al. 2021. Cell. 184(17):4447-4463.e20. PubMed
  31. Zhu Y, et al. 2019. Front Genet. 10:141. PubMed
  32. Ahmed R et al. 2019. Cell. 177(6):1583-1599 . PubMed
  33. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  34. Zucchetti AE, et al. 2019. Nat Commun. 10:2864. PubMed
  35. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  36. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
  37. Fasbender F, et al. 2017. Front Immunol. 0.88125. PubMed
  38. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  39. Tocheva AS, et al. 2020. J Biol Chem. 295:18036. PubMed
  40. Haas R, et al. 2015. PLoS Biol. 13: 1002202. PubMed
  41. Bobardt M, et al. 2020. PLoS One. 15:e0227715. PubMed
  42. Willimsky G, et al. 2021. Elife. 10:. PubMed
  43. Song C, et al. 2022. Stem Cell Res Ther. 13:48. PubMed
  44. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  45. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  46. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  47. Ye Z, et al. 2008. Infect Immun. 76:2541. PubMed
  48. Woolsey C, et al. 2020. Scientific Reports. 10(1):3071.. PubMed
  49. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
  50. Dias J, et al. 2018. Proc Natl Acad Sci U S A. 115:E11513. PubMed
  51. Oberg HH, et al. 2020. J Leukoc Biol. 107:1081. PubMed
  52. Gaa R, et al. 2021. MAbs. 13:1978130. PubMed
  53. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  54. Kondo H, et al. 2022. Front Immunol. 13:836923. PubMed
  55. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
  56. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  57. Meléndez AV, et al. 2022. Cell Mol Life Sci. 79:513. PubMed
  58. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  59. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  60. Guo T, et al. 2018. J Immunol. 200:500. PubMed
  61. Jin H, et al. 2019. MBio. 10:e01769-19. PubMed
  62. Jimenez RV, et al. 2019. Front Immunol. 1.932638889. PubMed
  63. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  64. O'Boyle KC, et al. 2020. Methods Mol Biol. 2111:1. PubMed
  65. Cai J, et al. 2021. eLife. 10:00. PubMed
  66. Kinosada H, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006120. PubMed
  67. Zhu Y, et al. 2019. Cell Stem Cell. 25:542. PubMed
  68. Ito T, et al. 2021. Commun Biol. 4:694. PubMed
  69. Liu Y, et al. 2022. Micromachines (Basel). 13:. PubMed
  70. Leonard J, et al. 2011. J Virol. 85:6867. PubMed
  71. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
  72. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
  73. Jakob M, et al. 2020. Cells. 10:. PubMed
  74. Tocheva AS, et al. 2020. J Biol Chem. 295:18036. PubMed
  75. Sattler A, et al. 2021. Am J Transplant. 21:87. PubMed
  76. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
  77. Pardons M, et al. 2019. PLoS Pathog. 15:e1007619. PubMed
  78. Gee MH, et al. 2018. Cell. 172:549. PubMed
  79. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
  80. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  81. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  82. Bonavia AS, et al. 2022. Front Immunol. 13:940030. PubMed
  83. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  84. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  85. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
  86. Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed
  87. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  88. Duque JSR, et al. 2022. Nat Commun. 13:3700. PubMed
  89. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  90. Sheng WY, et al. 2006. FEBS Lett. 580:6819. PubMed
  91. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
  92. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  93. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  94. Mazer M, et al. 2019. J Immunol. 203:2088. PubMed
  95. Nomura T, et al. 2012. J Virol. 86:6481. PubMed
  96. Naranbhai V, et al. 2022. Cell. . PubMed
  97. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  98. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  99. He Y, et al. 2021. eLife. 10:00. PubMed
  100. Jones N, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01516. PubMed
  101. Bantug GR, et al. 2018. Immunity. 48:542. PubMed
  102. Ren X, et al. 2021. Lab Chip. 21:1527. PubMed
  103. Xiao C, et al. 2021. STAR Protoc. 2:100789. PubMed
  104. Ravell JC, et al. 2020. J Clin Invest. 130:507. PubMed
  105. Martin E, et al. 2020. JCI Insight. :5. PubMed
  106. Umeda M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
RRID
AB_314303 (BioLegend Cat. No. 302901)
AB_314303 (BioLegend Cat. No. 302902)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, homodimer, 44 kD
Distribution

Mature T cells, thymocytes, NK cell subsets, plasma cells, EBV-positive B cells

Function
T cell costimulation
Ligand/Receptor
CD80, CD86
Cell Type
B cells, NK cells, Plasma cells, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. June CH, et al. 1994. Immunol. Today 15:321.
3. Linskey PS, et al. 1993. Annu. Rev. Immunol. 11:191.

Gene ID
940 View all products for this Gene ID
UniProt
View information about CD28 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD28 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD28 CD28.2 FC
Biotin anti-human CD28 CD28.2 FC
FITC anti-human CD28 CD28.2 FC
PE anti-human CD28 CD28.2 FC
PE/Cyanine5 anti-human CD28 CD28.2 FC
Purified anti-human CD28 CD28.2 FC,IHC-F,Costim,FA
Alexa Fluor® 488 anti-human CD28 CD28.2 FC
Alexa Fluor® 700 anti-human CD28 CD28.2 FC
PerCP/Cyanine5.5 anti-human CD28 CD28.2 FC
Pacific Blue™ anti-human CD28 CD28.2 FC
PE/Cyanine7 anti-human CD28 CD28.2 FC
Ultra-LEAF™ Purified anti-human CD28 CD28.2 FC,IHC-F,Costim,FA
Brilliant Violet 421™ anti-human CD28 CD28.2 FC
Brilliant Violet 510™ anti-human CD28 CD28.2 FC
Purified anti-human CD28 (Maxpar® Ready) CD28.2 FC,CyTOF®
PE/Dazzle™ 594 anti-human CD28 CD28.2 FC
Brilliant Violet 785™ anti-human CD28 CD28.2 FC
Brilliant Violet 650™ anti-human CD28 CD28.2 FC
Brilliant Violet 711™ anti-human CD28 CD28.2 FC
APC/Fire™ 750 anti-human CD28 CD28.2 FC
Alexa Fluor® 647 anti-human CD28 CD28.2 FC
TotalSeq™-A0386 anti-human CD28 CD28.2 PG
TotalSeq™-B0386 anti-human CD28 CD28.2 PG
TotalSeq™-C0386 anti-human CD28 CD28.2 PG
Brilliant Violet 605™ anti-human CD28 CD28.2 FC
APC/Cyanine7 anti-human CD28 CD28.2 FC
PE anti-human CD28 CD28.2 FC
APC anti-human CD28 CD28.2 FC
Brilliant Violet 750™ anti-human CD28 CD28.2 FC
PE/Fire™ 810 anti-human CD28 CD28.2 FC
GMP PE anti-human CD28 CD28.2 FC
TotalSeq™-D0386 anti-human CD28 CD28.2 PG
Spark Violet™ 423 anti-human CD28 CD28.2 FC
GMP Ultra-LEAF™ Purified anti-human CD28 SF CD28.2 FC,Costim
GMP APC anti-human CD28 CD28.2 FC
PE/Cyanine7 anti-human CD28 CD28.2 FC
GMP Ultra-LEAF™ Biotin anti-human CD28 SF CD28.2 FC,Activ
PerCP/Cyanine5.5 anti-human CD28 CD28.2 FC
Spark Blue™ 515 anti-human CD28 CD28.2 FC
Spark Red™ 718 anti-human CD28 CD28.2 FC
GMP PerCP/Cyanine5.5 anti-human CD28 CD28.2 FC
Go To Top Version: 3    Revision Date: 08.25.2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account